Definitive Proxy Filed for Eli Lilly Acquisition at $14.00/Share, Shareholder Vote Set for March 3, 2026

summarizeSummary

Ventyx Biosciences filed its definitive proxy statement for the all-cash acquisition by Eli Lilly and Company at $14.00 per share, with a special shareholder meeting scheduled for March 3, 2026, to vote on the merger.

check_boxKey Events

• Shareholder Meeting Scheduled

  A special meeting of common stockholders is set for March 3, 2026, to vote on the adoption of the merger agreement with Eli Lilly and Company.

• Merger Terms Reaffirmed

  The filing reaffirms the all-cash acquisition at $14.00 per common share and $1,400.00 per preferred share, consistent with prior announcements.

• Fairness Opinions Included

  Fairness opinions from Jefferies LLC and Moelis & Company LLC were provided to the Board, concluding that the $14.00 per share cash consideration is fair from a financial point of view to common stockholders.

• Board Recommends Approval

  The Ventyx Board of Directors unanimously recommends that shareholders vote 'FOR' the adoption of the merger agreement.

auto_awesomeAnalysis

This DEFM14A filing is the definitive proxy statement for Ventyx Biosciences' acquisition by Eli Lilly and Company, providing shareholders with comprehensive details to vote on the merger at a special meeting scheduled for March 3, 2026. The filing reaffirms the all-cash consideration of $14.00 per common share, which represents a significant premium to the stock's trading price prior to market speculation. The inclusion of fairness opinions from two independent financial advisors, Jefferies LLC and Moelis & Company LLC, supports the Board's recommendation that the deal is fair from a financial perspective. This definitive statement is a critical procedural step towards the completion of the previously announced merger, indicating that the transaction is progressing as planned and is highly likely to close.